Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly, acquired shares of common stock through a deferral plan, increasing her holdings.

Summary

• Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 13,637 shares of common stock at a price of $727.20 per share on November 18, 2024.
• These shares were acquired through the Lilly Directors' Deferral Plan, where the shares were deferred in lieu of cash compensation.
• Additionally, Ms. Sulzberger acquired 302.53 shares of common stock at the same price on the same date.
• The total number of shares beneficially owned by Ms. Sulzberger after these transactions is 2,516.624.
• The shares acquired through the deferral plan will be settled in shares of common stock following her separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director acquiring shares, which is generally viewed positively as it indicates confidence in the company. There are no negative implications.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The shares acquired through the deferral plan will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Director share acquisitions are a common occurrence in publicly traded companies and are often seen as a sign of confidence in the company's future performance.

Comparison to Industry Standards

• Director share acquisitions are a standard practice across publicly listed companies, including pharmaceutical companies like Eli Lilly.
• These transactions are typically disclosed through SEC filings like Form 4, ensuring transparency and compliance with regulations.
• The deferral plan used by Eli Lilly is a common method for compensating directors, aligning their interests with the long-term performance of the company.

Stakeholder Impact

• The share acquisition by a director may positively influence shareholder confidence.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Common Stock, Form 4, Gabrielle Sulzberger, Lilly Directors' Deferral Plan